Trial Profile
A Phase I/II Dose-Escalation Trial of Leflunomide in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Leflunomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 04 Oct 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently(Last verified Oct 2021).
- 15 Sep 2023 Status changed from active, no longer recruiting to completed.
- 04 Oct 2021 Planned End Date changed from 18 Sep 2021 to 18 Jan 2022.